
>%%
>```annotation-json
>{"created":"2022-08-08T05:57:41.165Z","updated":"2022-08-08T05:57:41.165Z","document":{"title":"Determining the Appropriate Treatment for T-Cell Acute Lymphoblastic Leukemia With SET-CAN/NUP214 Fusion: Perspectives From a Case Report and Literature Review","link":[{"href":"urn:x-pdf:2fef2038058f8988b22e09ab45457e1c"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf"}],"documentFingerprint":"2fef2038058f8988b22e09ab45457e1c"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","selector":[{"type":"TextPositionSelector","start":314,"end":485},{"type":"TextQuoteSelector","exact":"SET-CAN/NUP214 fusion is a recurrent event most commonly seen in T-cell acutelymphoblastic leukemia (T-ALL). It is related to resistance to glucocorticoids andchemotherapy","prefix":"ical University, Shenyang, China","suffix":"; however, the reported prognosi"}]}]}
>```
>%%
>*%%PREFIX%%ical University, Shenyang, China%%HIGHLIGHT%% ==SET-CAN/NUP214 fusion is a recurrent event most commonly seen in T-cell acutelymphoblastic leukemia (T-ALL). It is related to resistance to glucocorticoids andchemotherapy== %%POSTFIX%%; however, the reported prognosi*
>%%LINK%%[[#^uemvq2w5ps|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^uemvq2w5ps


>%%
>```annotation-json
>{"created":"2022-08-08T05:58:28.340Z","text":"pegaspargase 培门冬酶","updated":"2022-08-08T05:58:28.340Z","document":{"title":"Determining the Appropriate Treatment for T-Cell Acute Lymphoblastic Leukemia With SET-CAN/NUP214 Fusion: Perspectives From a Case Report and Literature Review","link":[{"href":"urn:x-pdf:2fef2038058f8988b22e09ab45457e1c"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf"}],"documentFingerprint":"2fef2038058f8988b22e09ab45457e1c"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","selector":[{"type":"TextPositionSelector","start":738,"end":1048},{"type":"TextQuoteSelector","exact":"early resistance to routine VICLP chemotherapy (at 15th day, 79.2% blasts),but the leukemia burden was significantly reduced after 28-day induction chemotherapy(18.85% blasts), even though she still didn’t achieve complete remission (CR) after a secondcourse of high-dose methotrexate (3 g/m2) and pegaspargase","prefix":"UP214 fusion. Thepatient showed ","suffix":". Ex vivo drug sensitivityscreen"}]}]}
>```
>%%
>*%%PREFIX%%UP214 fusion. Thepatient showed%%HIGHLIGHT%% ==early resistance to routine VICLP chemotherapy (at 15th day, 79.2% blasts),but the leukemia burden was significantly reduced after 28-day induction chemotherapy(18.85% blasts), even though she still didn’t achieve complete remission (CR) after a secondcourse of high-dose methotrexate (3 g/m2) and pegaspargase== %%POSTFIX%%. Ex vivo drug sensitivityscreen*
>%%LINK%%[[#^tj20ui5xvaa|show annotation]]
>%%COMMENT%%
>pegaspargase 培门冬酶
>%%TAGS%%
>
^tj20ui5xvaa


>%%
>```annotation-json
>{"created":"2022-08-08T06:00:00.991Z","text":"etoposide 依托泊苷\ncarfilzomib  卡非佐米","updated":"2022-08-08T06:00:00.991Z","document":{"title":"Determining the Appropriate Treatment for T-Cell Acute Lymphoblastic Leukemia With SET-CAN/NUP214 Fusion: Perspectives From a Case Report and Literature Review","link":[{"href":"urn:x-pdf:2fef2038058f8988b22e09ab45457e1c"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf"}],"documentFingerprint":"2fef2038058f8988b22e09ab45457e1c"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","selector":[{"type":"TextPositionSelector","start":1295,"end":1418},{"type":"TextQuoteSelector","exact":"AML-like scheme DAE scheme(daunorubicin + cytarabine + etoposide) and carfilzomib showed the highest ex vivoinhibition rate","prefix":"various regimens. Surprisingly, ","suffix":". The patient received DAE regim"}]}]}
>```
>%%
>*%%PREFIX%%various regimens. Surprisingly,%%HIGHLIGHT%% ==AML-like scheme DAE scheme(daunorubicin + cytarabine + etoposide) and carfilzomib showed the highest ex vivoinhibition rate== %%POSTFIX%%. The patient received DAE regim*
>%%LINK%%[[#^83khgrfi8x5|show annotation]]
>%%COMMENT%%
>etoposide 依托泊苷
>carfilzomib  卡非佐米
>%%TAGS%%
>
^83khgrfi8x5


>%%
>```annotation-json
>{"created":"2022-08-08T06:01:24.319Z","updated":"2022-08-08T06:01:24.319Z","document":{"title":"Determining the Appropriate Treatment for T-Cell Acute Lymphoblastic Leukemia With SET-CAN/NUP214 Fusion: Perspectives From a Case Report and Literature Review","link":[{"href":"urn:x-pdf:2fef2038058f8988b22e09ab45457e1c"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf"}],"documentFingerprint":"2fef2038058f8988b22e09ab45457e1c"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","selector":[{"type":"TextPositionSelector","start":1636,"end":1807},{"type":"TextQuoteSelector","exact":" we found that T-ALL patientswith SET-CAN/NUP214 fusion usually shows early resistance to chemotherapy, but theyhave a delayed response, and the CR rate is not compromised","prefix":"indings and a literature survey,","suffix":"; thus, a chemotherapyregimen fe"}]}]}
>```
>%%
>*%%PREFIX%%indings and a literature survey,%%HIGHLIGHT%% ==we found that T-ALL patientswith SET-CAN/NUP214 fusion usually shows early resistance to chemotherapy, but theyhave a delayed response, and the CR rate is not compromised== %%POSTFIX%%; thus, a chemotherapyregimen fe*
>%%LINK%%[[#^s4stkil3lzg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^s4stkil3lzg


>%%
>```annotation-json
>{"created":"2022-08-08T06:01:48.488Z","updated":"2022-08-08T06:01:48.488Z","document":{"title":"Determining the Appropriate Treatment for T-Cell Acute Lymphoblastic Leukemia With SET-CAN/NUP214 Fusion: Perspectives From a Case Report and Literature Review","link":[{"href":"urn:x-pdf:2fef2038058f8988b22e09ab45457e1c"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf"}],"documentFingerprint":"2fef2038058f8988b22e09ab45457e1c"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","selector":[{"type":"TextPositionSelector","start":1943,"end":2048},{"type":"TextQuoteSelector","exact":".Forrefractorypatients,AML-liketherapysuchasDAEorCLAG in combination with asparaginase may be beneficial.","prefix":"isrecommendedforinductiontherapy","suffix":" In addition, carfilzomib may be"}]}]}
>```
>%%
>*%%PREFIX%%isrecommendedforinductiontherapy%%HIGHLIGHT%% ==.Forrefractorypatients,AML-liketherapysuchasDAEorCLAG in combination with asparaginase may be beneficial.== %%POSTFIX%%In addition, carfilzomib may be*
>%%LINK%%[[#^7i3udjxlscr|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^7i3udjxlscr


>%%
>```annotation-json
>{"created":"2022-08-08T06:02:26.532Z","updated":"2022-08-08T06:02:26.532Z","document":{"title":"Determining the Appropriate Treatment for T-Cell Acute Lymphoblastic Leukemia With SET-CAN/NUP214 Fusion: Perspectives From a Case Report and Literature Review","link":[{"href":"urn:x-pdf:2fef2038058f8988b22e09ab45457e1c"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf"}],"documentFingerprint":"2fef2038058f8988b22e09ab45457e1c"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fonc-11-651494.pdf","selector":[{"type":"TextPositionSelector","start":3579,"end":3656},{"type":"TextQuoteSelector","exact":"such as the PML/RAR and AML/ETO rearrangements in acute myeloid leukemia(AML)","prefix":" selections in acute leukemias, ","suffix":". SET-CAN/NUP214 fusion is forme"}]}]}
>```
>%%
>*%%PREFIX%%selections in acute leukemias,%%HIGHLIGHT%% ==such as the PML/RAR and AML/ETO rearrangements in acute myeloid leukemia(AML)== %%POSTFIX%%. SET-CAN/NUP214 fusion is forme*
>%%LINK%%[[#^78jstbgagp3|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^78jstbgagp3
